7) Given results of CAPRISA
004, the next step is to try to conduct an expanded safety studies in youth using antiretroviral-based microbicides.
Overall, however, it was not felt that the landmark CAPRISA
trial had provided all of the answers needed to introduce use of 1% tenofovir gel as a new HIV prevention strategy.
004 trial recently provided the first evidence that tenofovir gel used before and after sex can prevent HIV infection in women (31) contrary to past predictions (32).
004, a proof-of-concept trial, ran at two South African clinic locations: a rural site in the KwaZulu-Natal Midlands, and an urban site in Durban.
associate director of CAPRISA
and an epidemiologist at Columbia, who ran the study with her husband and reported the results along with him.
004 enrolled 980 South African women with a high HIV risk and randomized them to use 1% tenofovir gel or placebo.
DIA is recognizing the seven scientists who comprised the leadership team of the study (known as CAPRISA
004) which provided the first evidence that antiretroviral drugs can prevent the sexual transmission of HIV in women.
2,16] Two randomised controlled trials undertaken in SA (HPTN 068 and CAPRISA
007) were unable to demonstrate any impact on HIV acquisition as a result of lower than anticipated HIV incidence rates.
These results, of the CAPRISA
004 trial, were released in July 2010.
Statistical modeling conducted by CAPRISA
004 researchers estimate that this microbicide can prevent up to 1.
That study, the CAPRISA
004 trial, tested topical pre-exposure prophylaxis with 1 percent tenofovir which participants were instructed to apply vaginally twice daily.
The HPTN 052 study provides compelling evidence for a new HIV prevention approach that links prevention and care efforts," said Quarraisha Abdool Karim, HPTN co-principal investigator and associate scientific director of CAPRISA